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Role of a Vertebrate-Specific Branch of Chaperonin-Related
Proteins in Bardet-Biedl Syndrome
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Bardet-Biedl syndrome (BBS) is primarily an autosomal recessive ciliopathy characterized by progressive retinal degen-
eration, obesity, cognitive impairment, polydactyly, and kidney anomalies. The disorder is genetically heterogeneous,
with 11 BBS genes identified to date, which account for ∼70% of affected families. We have combined single-nucleotide–
polymorphism array homozygosity mapping with in silico analysis to identify a new BBS gene, BBS12. Patients from two
Gypsy families were homozygous and haploidentical in a 6-Mb region of chromosome 4q27. FLJ35630 was selected as
a candidate gene, because it was predicted to encode a protein with similarity to members of the type II chaperonin
superfamily, which includes BBS6 and BBS10. We found pathogenic mutations in both Gypsy families, as well as in 14
other families of various ethnic backgrounds, indicating that BBS12 accounts for ∼5% of all BBS cases. BBS12 is vertebrate
specific and, together with BBS6 and BBS10, defines a novel branch of the type II chaperonin superfamily. These three
genes are characterized by unusually rapid evolution and are likely to perform ciliary functions specific to vertebrates
that are important in the pathophysiology of the syndrome, and together they account for about one-third of the total
BBS mutational load. Consistent with this notion, suppression of each family member in zebrafish yielded gastrulation-
movement defects characteristic of other BBS morphants, whereas simultaneous suppression of all three members resulted
in severely affected embryos, possibly hinting at partial functional redundancy within this protein family.
From the Laboratoire de Ge´ne´tique Me´dicale, Faculte´ de Me´decine, Universite´ Louis Pasteur (C.S.; V.L.; C.J.; J.-M.D.; H.D.), and Service de Ge´ne´tique
Me´dicale et Centre de Re´fe´rence pour les Affections Ge´ne´tiques Ophtalmologiques, Centre Hospitalier Universitaire (V.L.; H.D.), Strasbourg, France;
Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, Inserm Unite´ 596, Centre National de la Recherche Scientifique (J.M.; S.V.; F.P.; C.T.; O.P.;
J.-L.M.), and Colle`ge de France (J.-L.M.), Illkirch, France; Laboratoire de Biologie Mole´culaire, d‘Analyse Ge´nique et de Mode´lisation, Centre de Recherche
Public-Sante´, Luxembourg (J.M.; E.F.); McKusick-Nathans Institute of Genetic Medicine and Departments of Ophthalmology and Molecular Biology and
Genetics, John Hopkins University, Baltimore (E.E.D.; N.A.Z.; C.C.L.; N.K.); Service de Ge´ne´tique Me´dicale, Centre Hospitalier Universitaire (CHU) Hoˆpital
Arnaud de Villeneuve (P.S.), and Institut des Neurosciences de Montpellier, CHU Hoˆpital Saint-Eloi (C.H.), Montpellier, France; Centre for Human Genetics,
University Hospital Gasthuisberg, Leuven, Belgium (T.J.L.d.R.); Departments of Ophthalmology, Pediatrics, and Molecular and Human Genetics, Baylor
College of Medicine, Houston (R.A.L.); Unite´ de Ge´ne´tique Clinique, Hoˆpital Robert Debre´, Paris (A.V.); and Service de Ge´ne´tique, CHU, Angers, France
(D.B.)
Received July 21, 2006; accepted for publication October 17, 2006; electronically published November 15, 2006.
Address for correspondence and reprints: Dr. He´le`ne Dollfus, Laboratoire de Ge´ne´tique Me´dicale, EA 3439, Faculte´ de Me´decine, Hoˆpitaux Universitaires
de Strasbourg, 11 rue Humann, 67085 Strasbourg, France. E-mail: helene.dollfus@medecine.u-strasbg.fr
* These two authors contributed equally to this work.
Am. J. Hum. Genet. 2007;80:1–11.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2007/8001-0002$15.00
Bardet-Biedl syndrome (BBS [MIM 209900]) is a clinically
pleiotropic disorder transmitted primarily in an autosomal
recessive fashion, and its hallmarks include progressive
retinal degeneration, obesity, polydactyly, hypogenital-
ism, cognitive impairment, and kidney dysplasia.1,2 Its in-
cidence has been estimated to be 1 in 150,000 individuals
in European populations but is much higher in some pop-
ulations with a high level of consanguinity (e.g., the Mid-
dle East and North Africa) or that are geographically iso-
lated (e.g., Newfoundland).3–5 Since 1994,6 the use of
homozygosity mapping in consanguineous families with
BBS allowed the progressive recognition of a surprisingly
high level of nonallelic genetic heterogeneity. Since the
identification of the first gene in 2000 (BBS6, also called
“MKKS” because it is mutated in the closely related
McKusick-Kaufmann syndrome),7,8 mutations have been
found in a total of 11 genes (BBS1–BBS11) in patients with
BBS.9–19 Recent molecular evidence has revealed an un-
expected connection between the BBS proteins and pri-
mary cilia, microtubule-based structures arising from the
basal body that are notably involved as mechanosensors
in kidney epithelium, in the organization of photoreceptor
cells of the retina, and in the developmental phenomenon
of planar cell polarity.14,20,21 This allowed the characteri-
zation of BBS as one of the ciliopathies, an expanding
group of clinically distinct but overlapping disorders that
includes autosomal dominant polycystic kidney disease,
nephronophthisis, Alstro¨m syndrome, orofaciodigital syn-
drome type 1, and, most recently, Meckel and Joubert
syndromes.21,22 The remarkable conservation of ciliary and
basal-body proteins across phyla has catalyzed the iden-
tification of several BBS genes, on the basis of the as-
sumption that these genes are conserved exclusively in
ciliated organisms, such as Chlamydomonas, but are absent
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from nonciliated ones, such as Arabidopsis.12,16,17 However,
this approach is insufficient to identify all genes mutated
in this phenotype, as highlighted by the recent identifi-
cation of the vertebrate-specific BBS10 locus.18 In fact, the
first BBS gene identified (BBS6, or MKKS) and BBS10 are
absent from all ciliary data sets, including the recently
constructed, manually curated Ciliary Proteome Data-
base.23 Interestingly, BBS6 and BBS10 are both atypical
members of the superfamily of type II chaperonins, on
the basis of a distant sequence homology.18,24
The extensive genetic heterogeneity of BBS has pro-
found implications for diagnostic and genetics-counseling
applications. Two major genes, BBS1 and BBS10, each ac-
count for ∼20% of the mutational load in families of Eu-
ropean descent, whereas each of the other nine genes ac-
counts for 5%, and some of these were found mutated
in only a few families or even a single family (the latter
in the case of BBS11).18,19,25 Taken together, the 11 known
BBS genes account for ∼70% of affected families,18 sug-
gesting that additional BBS genes remain to be identified.
A further complication is the finding that, in some cases,
inheritance departs from classic autosomal recessive in-
heritance and involves three mutated alleles in two genes,
defining oligogenic inheritance, and severity can be mod-
ulated by an allele of a modifier gene.25,26
Here, we report the identification of BBS12 on chro-
mosome 4q27, starting with homozygosity mapping in
two consanguineous Gypsy families with BBS. In silico
studies pointed to a candidate gene, FLJ35630, which en-
codes a predicted chaperonin-like protein. We found mu-
tations in both Gypsy families as well as in other BBS-
affected families, suggesting that this novel locus accounts
for some 5% of the overall mutational load of families
with BBS.
BBS12, together with BBS6 and BBS10, defines a new
vertebrate-specific and divergent branch of chaperonin-
like proteins with particular sequence insertions, with re-
spect to the typical group II chaperonins. Suppression of
each member of the family in zebrafish recapitulated pre-
viously reported bbs morphant phenotypes,26 whereas
combinatorial suppression of bbs6, bbs10, and bbs12 re-
vealed strong genetic interaction, with the embryos ex-
hibiting markedly more-severe phenotypes when all three
chaperonin-like proteins were suppressed simultaneously.
This branch of atypical chaperonins is of major impor-
tance for BBS, since the three genes together account for
about one-third of the mutational load.
Patients and Methods
The patients analyzed in this study came from two cohorts, one
recruited in France and one in the United States. The clinical
inclusion criteria were defined elsewhere.1 Appropriate informed
consent was obtained from all participants in the study, with
respect to the tenets of the Declaration of Helsinki.
For the French cohort, 1200 families with BBS have been col-
lected during the past 3 years. Nine families that did not show
any mutation in the BBS1–BBS10 genes were selected for a first
screen by SNP array analysis because of consanguinity and/or
because of the number of affected individuals. A second series of
106 patients with BBS, comprising mostly sporadic cases, was
tested for mutations. We excluded from the testing any families
that had two bona fide pathologic alleles in other BBS genes. For
the US cohort, a series of 139 patients with BBS was tested, with-
out preselection against probands with previously known BBS
mutations.
SNP Homozygosity Mapping
Affected and unaffected siblings from consanguineous families
were studied with the Affymetrix GeneChip Mapping 10K Array
(Affymetrix). These arrays allow analysis of 10,000 SNPs with a
mean genetic gap distance of 0.32 cM and an average heterozy-
gosity of 0.37.
Sample processing and labeling were performed in accordance
with the manufacturer’s instructions (Affymetrix Mapping 10K
2.0 Assay Manual, version 1.0). The arrays were hybridized on a
GeneChip Hybridization Oven 640, were washed with a Gene-
Chip Fluidics Station 450, and were scanned with a GeneChip
Scanner 3000. Data were processed by the GeneChip DNA Anal-
ysis Software version 3.0.2, to generate SNP allele calls. An average
call rate 199% was obtained. Homozygosity regions were iden-
tified as regions of homozygosity comprising 125 adjacent SNPs.
One of us (F.P.) has developed a graphic interface (fig. 1A) that
allows an easy comparison of homozygous regions between pa-
tients or unaffected siblings from different families, including a
majority of small families that have limited informativeness for
linkage and that are each consistent with BBS linkage to 2–5
chromosomal regions.
DNA Analysis with Microsatellite Markers
Genotyping of additional fluorescent microsatellite markers was
performed on a CEQ8800 genetic analysis system (Beckman Coul-
ter). Experimental conditions are available on request. Microsat-
ellite sequences were obtained from the UCSC Genome Browser.
DNA Sequencing and Mutation Screening
PCR amplifications of exon 2 of FLJ35630 were performed with
50 ng of genomic DNA template per amplicon (see table 1 for
oligonucleotide primers). The noncoding exon 1 was screened for
all the US families and for one family in the French cohort (family
III.10). Bidirectional sequencing of the purified PCR products was
performed as described elsewhere.18
Database Searches
Systematic exploration in UniProt was performed with BLASTP
on each candidate gene in the interval of interest. For each gene,
the sequences detected with expect value !103 were aligned with
the PipeAlign program.
For BBS12, a PSI-BLAST in UniProt and RefSeq was performed
using a protein sequence from UniProt, accession number
Q6ZW61_HUMAN, as the query and was used to obtain a multiple
alignment as described elsewhere.18 The multiple alignment was
manually adjusted, with attention paid to secondary structures,
leading to nearly 300 sequences corresponding to a, b, g, d, , z,
h, and v chaperonin-containing TCP1 (CCT) chaperonin subunits,
archeal chaperonins, BBS6, BBS10, and BBS12 sequences. The
Figure 1. Mapping of a candidate BBS region to 4q27. A, Analysis of homozygosity in chromosome 4 in three consanguineous families.
The areas of homozygosity with 125 SNPs are black, whereas homozygosity regions defined by 15–25 consecutive SNPs are gray.
B, Detailed SNP homozygosity mapping and microsatellite segregation in the region of interest on chromosome 4 in the two Gypsy
families. Light- and dark-gray regions represent homozygous SNPs (AA and BB, respectively), whereas white regions indicate heterozygous
alleles (AB).
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Table 1. Primer Sequences for BBS12
Exon and
Amplicon
Primer Sequence
(5′r3′)
Size
(bp)Forward Reverse
Exon 1 CGCAGCCCGGCGTTAAGCGG CCCTGGCCCGAAGAGGACAG 508
Exon 2:
Amplicon 1 GCAGGGAGCATATCTTGTTT CTACCTCTTCACTACAAAAG 482
Amplicon 2 GGAGCAGTGCAGTTGAAGAA GAGTAGCTGTAACATGTTCTTG 495
Amplicon 3 CCTGCTGCAGACAGTCAATA GCCCACAGTTCTTCTGAGCT 520
Amplicon 4 GAGGGTGACCTCACAGAGAA GCCAGAGATGAAGCCAGCCA 665
Amplicon 5 GGTCTTCCTTGGAGGTGGTG GGCACCATGACTTGGCTATC 616
multiple sequence alignment is available at Bardet Biedl Syn-
drome: Multiple Alignment Web site.
Phylogenetic Tree
A phylogenetic tree was built with Phylo_win by use of repre-
sentative sequences from each different chaperonin subunit and
from BBS12, BBS10, and BBS6. The parameters were set to global
gap removal by use of the neighbor-joining method. Branches
were tested by bootstrapping (500 replicates), and the tree was
edited and displayed with TreeView. The multiple alignment used
for phylogenetic analyses contains 211 positions between the se-
lected sequences.
Phylogenetic Distribution of BBS12 in Complete Genomes
Phylogenetic distribution of BBS12 was examined in 42 eukar-
yotic organisms for which the genome sequences are available.
The presence or absence of each BBS12 was cross-validated at both
the proteomic and genomic levels.
The 42 eukaryotic genomes used were Homo sapiens, Mus mus-
culus, Rattus norvegicus, Gallus gallus, Xenopus laevis, Tetraodon
nigroviridis, Danio rerio, Takifugu rubripes, Ciona intestinalis,
Strongylocentrotus purpuratus, Drosophila melanogaster, Anopheles
gambiae, Apis mellifera, Caenorhabditis elegans, Caenorhabditis
briggsae, Schizosaccharomyces pombe, Saccharomyces cerevisiae, Can-
dida albicans, Candida glabrata, Kluyveromyces lactis, Ashbya (Ere-
mothecium) gossypii, Debaryomyces hansenii, Yarrowia lipolytica, As-
pergillus fumigatus, Neurospora crassa, Cryptococcus neoformans,
Encephalitozoon cuniculi, Dictyostelium discoideum, Entamoeba his-
tolytica, Thalassiosira pseudonana, Trypanosoma cruzi, Leishmania
major, Plasmodium falciparum, Cryptosporidium parvum, Cryptospo-
ridium hominis, Theileria parva, Tetrahymena thermophila, Giardia
lamblia, Arabidopsis thaliana, Oryza sativa, and Cyanidioschyzon
merolae.
When available, the genomic sequences were queried by
TBLASTN within the corresponding nucleotide-sequence data-
base from the National Center for Biotechnology Information
(NCBI) (including GenBank and RefSeq), UCSC Genome Browser,
or Ensembl Genome Browser. We also used dedicated Web sites
to retrieve the latest sequence version for C. briggsae (WormBase),
T. pseudonana (JGI: T. pseudonana), D. discoideum (dictyBase), E.
histolytica and L. major (The Wellcome Trust Sanger Institute),
O. sativa (Rice Information System), and T. thermophila (The In-
stitute for Genomic Research) and other sites for additional BLAST
searches for cryptosporidia (CryptoDB) and C. merolae (Cyani-
dioschyzon merolae Genome Project). The putative BBS12 se-
quences were created for the following six vertebrate genomes:
Bos taurus, Canis familiaris, X. laevis, D. rerio, T. rubripes, and T.
nigroviridis.
Comparative Sequence Analysis of All Known BBS Genes
When available, the BBS1–BBS11 protein sequences from H. sap-
iens to C. elegans were retrieved from protein databases and were
aligned using the same protocol as for BBS12. Sequence identities
and similarities were computed for each member of the BBS1–
BBS11 family as the pairwise percent identity of each sequence
against the human protein sequence. Positions in the alignment
of these sequences corresponding to gaps were excluded from the
calculation.
Embryo Collection and Morpholino (MO) Injection
Embryos were collected from natural matings of wild-type zebra-
fish immediately after fertilization. A translational MO against
bbs12 was designed (Gene Tools) and was diluted to various con-
centrations for dose-response assays. For genetic interaction as-
says, 1 ng of bbs12 MO was injected, along with 4 ng of bbs6 MO
and 6 ng of bbs10 MO. For all injections, 1 nl of solution was
injected into one- to two-cell–stage embryos. Embryos were
scored at midsomite stages.
Results
Identification of a Candidate Region on Chromosome 4q27
by Homozygosity Mapping
We analyzed probands from nine consanguineous and/or
multiplex BBS-affected families with the 10K Affymetrix
SNP array. A search for all common regions of homozy-
gosity suggested potential linkage of three families (V.3,
III.12, and III.10) to 4q27 (fig. 1A), included in the broader
4q24-q32.2 (58-Mb) region proposed recently as a can-
didate region for a novel BBS locus on the basis of a similar
analysis with a different cohort.17 This region also contains
the BBS7 gene described elsewhere.15 Analysis of unaf-
fected sibs was consistent with the suggestive linkage, al-
lowing us to restrict the candidate region to a 6-Mb region
extending from 118.87 Mb to 124.77 Mb (fig. 1B). Inter-
estingly, the three patients in families V.3 and III.12,
known to be of Gypsy (Roms) origin, were haploidentical
for a region of 47 Mb, including the region of interest,
which suggests that they share a common mutation by
descent (fig. 1B). The two families were not known to be
related and are partially settled in two different regions of
France.
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Table 2. Mutations Detected in BBS12 in Families with BBS
Family
Amino Acid Change Nucleotide Change
Ethnic
Origin
Other Mutated
BBS GenesAllele 1 Allele 2 Allele 1 Allele 2
V.3; III.12 R355X R355X 1063CrT 1063CrT Gypsy NDD
VII.7 V113del V113del 335delTAG 335delTAG Chinese NDD
III.17 F90fsX112 T501M 268delT 1502CrT White NDD
IV.15 N506K/P507del G630fsX638 1518delCCC 1890delCT White NDD
I.1 E495fsX498 E495fsX498 1483delGA 1483delGA Kurdish NDD
I.11; VII.16 F372fsX373 F372fsX373 1114delTT 1114delTT White NDD
I.7 T257fsX266 T257fsX266 769insA 769insA Algerian BBS3a (R122Q/N)
III.30 A289P A289P 865GrC 865GrC White NDD
V.6 G594fsX605 G630fsX638 1779insA 1890delCT White NDD
I.14 P159L I346T 476CrT 1037TrC White NDD
AR 198-04 F372fsX373 G540V 1114delTT 1619GrT White NDD
AR 273-04 F372fsX373 Q511-Q513 del 1114delTT 1529delACAGATGCA White NDD
AR 316-03 E365fsX382 X711Y-X728 1092delA 2133GrC White NDD
AR 14-04 G540V … 1619GrT … White NDD
NOTE.—The family numbering is done according to the laboratories’ coding. NDD p no other mutation detected to date.
a Mutation of uncertain pathogenecity.
We investigated this 6-Mb region for candidate genes.
Forty genes were listed in Ensembl, of which 23 are well
characterized (including BBS7 at position 122.97 Mb),
whereas 17 have minimal function annotation. Sequenc-
ing of the 19 exons of BBS7 in the three families did not
reveal any mutations.
Selection of Candidate Genes in the 4q26-q27 Region
After systematic bioinformatic analysis of genes in the
candidate interval—encompassing database searches and
multiple alignment analysis—we prioritized six genes for
screening; three were listed in the cilia-related compara-
tive genomic data sets23 (PRSS12, SEC24D, and SPATA5),
whereas three others were selected because of an expres-
sion pattern or putative function compatible with BBS or
with a ciliopathy. Of particular note was one transcript of
unknown function, FLJ35630, annotated in the genome
as “C4orf24,” that showed distant homology to group II
chaperonins and to the previously identified BBS10 and
BBS6 genes.
Sequencing of FLJ35630 in Two Gypsy Families
FLJ35630 consists of two exons, of which only the second
is coding, for a predicted protein of 710 aa. Sequencing
of exon 2 in the two Gypsy families revealed a homozy-
gous C1062T change that induces a R355X nonsense mu-
tation, which was present in all patients of both families
(individuals V.3.C, III.12.C, and III.12.D). The parents
were heterozygous, and none of the seven unaffected sibs
were homozygous for this mutation, suggesting that mu-
tations in FLJ35630 cause BBS, which thereby designates
the 12th locus for the disorder, BBS12. No mutation was
found in exons 1 and 2 in the third family (III.10), which
showed putative linkage in the same region. Other poten-
tially linked regions of homozygosity were detected for
this family with low informativeness (maximum expected
LOD score 1.32).
Sequencing of FLJ35630 in Other Families with BBS
To confirm the causality of BBS12 and to assess its con-
tribution to the total BBS mutational load, we sequenced
an additional 245 unrelated probands with BBS from the
French and US cohorts. The French series included 30 BBS-
affected families with no mutation identified in BBS1–
BBS8 and BBS10 (BBS9 and BBS11 have not been tested
yet) and 76 families tested partially for BBS genes, in which
either no mutation or only a single one have yet been
identified. We found homozygous or compound hetero-
zygous likely pathogenic mutations in 10 of these 106
families (table 2). For the US cohort, we sequenced 139
families without preselection against families with mu-
tations in another BBS gene. Three of these families were
compound heterozygotes, each carrying one mutation
causing a frameshift and premature termination and an-
other mutation affecting the protein sequence. The pro-
band of a fourth family had a single missense mutant allele
(G540V) that is probably deleterious (see below).
Overall, we identified 16 BBS-affected families with
pathogenic mutations (table 2), suggesting that BBS12 mu-
tations account for ∼5% of families with BBS. Patients with
mutations in BBS12 did not present obvious phenotypic
differences compared with patients with mutations in
other known BBS genes.
Overall, we found 17 different mutations, including 7
frameshifts, 1 nonsense mutation, 1 mutation that is pre-
dicted to extend the C-terminus of the protein, and 3 small
in-frame deletions (fig. 2A). One of the frameshift muta-
tions is recurrent and present in six alleles (four families).
Five missense mutations were identified. One family was
homozygous for an A289P mutation affecting a conserved
residue. G540V and T501M were found in trans of frame-
shift mutations and correspond to nonconservative
changes. G540V was also found in the heterozygous state
in an additional patient for whom the second mutation
was not detected (a large deletion cannot be excluded at
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Figure 2. Schematic of the BBS12 locus and the position and/or nature of mutations. A, BBS12 genomic locus (top), corresponding
to FLJ35630 (NCBI [RefSeq] accession number NM_152618). FLJ35630 encodes a predicted protein of 710 aa (UniProt accession number
Q6ZW61_HUMAN). The bottom section is a schematic of the protein with the recognized domains in different colors (see key). The
insertions in the intermediate and equatorial domains are shown as yellow boxes above the protein. All reported mutant alleles are
shown underneath the protein. B, Phylogenetic tree of the BBS family. The tree contains BBS12, BBS10, and BBS6 sequences and
representative sequences from all group II chaperonins. BBS12 genes are highlighted with organism abbreviations, and predicted
sequences are marked with a black star. XL p X. laevis; GG p G. gallus; MM p M. musculus; RN p R. norvegicus; BT p B. taurus;
CFp C. familiaris; HSp H. sapiens; PPp Pongo pygmaeus; DRp D. rerio; TNp T. nigroviridis; TRp T. rubripes. The roots of vertebrate
branches are highlighted with gray dots. Bootstrap values are provided for significant nodes when they are 180%. C, Comparison of
BBS chaperonin-like domain organization. BBS12, BBS10, and BBS6 are represented with the typical chaperonin group II organization
in three domains (equatorial, intermediate, and apical). Specific insertions to the typical chaperonin group II are drawn in yellow and
are numbered in order of appearance from N-ter to C-ter part. Points of insertions that appear common to BBS12 and BBS6 and to
BBS12 and BBS10 are highlighted with black lines. D, Ribbon drawing of group II chaperonin a subunit (Protein Data Bank 1q2v).
Domains are colored according to figure 3A. BBS12 insertions (In1-In5) relative to all group II chaperonin sequences are represented
as yellow dashed rectangles.
this point). One patient was a compound heterozygote for
P159L and I346T; both changes are nonconserved. The
P159 residue is not conserved in evolution, whereas I346T
is chemically conserved (hydrophobic residue or A re-
places I in some vertebrate organisms). All missense
changes were not observed in 288 control chromosomes
and are not recorded in the dbSNP database. However,
functional testing will be necessary to assess definitively
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Figure 3. Sequence conservation of BBS proteins in vertebrates.
The percent identities are given from human to the nematode by
use of the human sequence as a reference. HS p H. sapiens;
CFp C. familiaris; MMp M. musculus; RNp R. norvegicus; GGp
G. gallus; DR p D. rerio; TN p T. nigroviridis; CE p C. elegans.
No BBS6, BBS10, and BBS12 orthologues exist in the C. elegans
genome.
their pathogenicity. We also observed four likely non-
pathogenic variants (G15G, I39T, I170V, and V354V) that,
although not previously reported in dbSNP, were found
in our controls. All missense mutations are shown on the
multiple sequence alignment (Bardet Biedl Syndrome:
Multiple alignment Web site).
The French cohort was not tested for oligogenism be-
cause families with two clearly pathogenic mutations in
a single BBS gene were excluded from testing. Testing in
US families was unbiased, since it included families with
two mutated alleles. However, there is no conclusive evi-
dence at present that BBS12 is significantly involved in
oligogenic inheritance, since we observed only one family
with two truncating mutations in BBS12 and a missense
variant of uncertain significance in BBS3 (family I.7) or a
few families with two mutations in other BBS genes and
a missense variant of BBS12 also found in controls or that
appears nonpathogenic (I170V) (not shown).
A Separate Branch of Type II Chaperonin Superfamily,
Defined by BBS12, BBS6, and BBS10
Extensive database searches and sequence analyses re-
vealed various BBS12 homologues and clearly relate BBS12
to the group II chaperonins and to a family of chaperonin-
like sequences encompassing BBS10 and BBS6 (fig. 2B). As
a result of the growing number of completely sequenced
genomes available, the distribution of BBS12 across the
eukaryotic phyla could be achieved by an in-depth anal-
ysis of the proteomes and genomes of 42 organisms. Like
BBS10 and BBS6, BBS12 is only present in vertebrates, from
fish to human (a distant BBS6 homologue, however, has
been reported in the urochordate C. intestinalis).24 The
analysis of the multiple alignments of complete represen-
tative sequences27 for all known chaperonin subunits and
chaperonin-like proteins revealed the conservation of the
classical chaperonin domain architecture (equatorial, in-
termediate, and apical domains)28 and the existence of
specific insertions. Compared with the prototypic group
II chaperonin, BBS12 contains five specific insertions in
the intermediate and equatorial domain: one large inser-
tion, In1 (82 aa at position 137); In2 (20 aa at position
241); In3 (25 aa at position 282); In4 (9 aa at position
557); and In5 (34 aa at position 612) (fig. 3C). In1 and
In3 protrude from the same face of the molecule, sug-
gesting that, like BBS10, they may cooperate to define an
additional domain in BBS12 (fig. 2D). It is notable that
the comparison of the positions of insertions with respect
to the typical group II chaperonin sequence for BBS12,
BBS10, and BBS6 reveals common insertion points, with-
out detectable homology between any of the insertions.
Indeed, BBS12 shares with BBS6 the same positions in the
core chaperonin fold for In4 and In5 and with BBS10 for
In2 and In3 (fig. 2C). In addition, the functional motif
GDGTT[T/S]28 responsible for ATP hydrolysis in all typical
group II chaperonins is not conserved in BBS12 and its
orthologues, in that regard resembling BBS6.24
Examination of a phylogenetic tree of the 12 subfamilies
of the type II chaperonin superfamily also indicates clearly
that the three BBS chaperonin-like molecules constitute a
separate branch from the eight eukaryotic CCT chaperon-
ins (a to z) or the archeobacteria subfamily (thermosome
TF55).29 The branch lengths from vertebrate separation
(indicated by a gray dot in fig. 2B) are much longer for
the three BBS subfamilies than for the eight eukaryotic
CCT subfamilies, indicating that the former have evolved
faster in vertebrates.
Conservation of the BBS12 protein in vertebrates was
also compared with that of the other known BBS proteins
(fig. 3). The three chaperonin-like proteins (BBS6, BBS10,
and BBS12) share a similar pattern of rapid sequence
change that is strikingly different from the pattern of
much greater conservation exhibited by all other known
BBS proteins.
Suppression of BBS12 and Other BBS Chaperonins
and Affect on Zebrafish Development
To assess the function of BBS12 in vivo, we investigated
the effects of suppression of bbs12 in zebrafish, taking
advantage of the BBS-related phenotypes in this model
that we reported elsewhere.20,26 Consistent with most
other known ciliary and all BBS genes, we found the ze-
brafish genome to contain a single copy of the likely BBS12
orthologue, to which we designed an oligonucleotide MO
to block protein translation. Injection of the MO into
wild-type embryos at progressively increasing concentra-
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Figure 4. CE defects and genetic interaction between the BBS chaperonins in zebrafish. A and B, Side (A) and dorsal (B) views of
live embryos injected either with a control MO, or various translational blocking MOs against the chaperonin-like subclass of bbs genes.
C, Distribution of phenotypes resulting from suppressing various combinations of bbs6, bbs10, and bbs12. Note the synthetic effect of
double suppression and the pronounced effect of the combinatorial suppression of all three genes, with the expansion of the severe
class of morphants (class II) being particularly prominent.
tions produced dose-dependent effects, which could be
rescued by coinjection of a capped bbs12 mRNA that es-
caped MO suppression. We observed phenotypes consis-
tent with convergence and extension (CE) defects, in-
cluding shortened body axis, broadened somites, kinked
notochord, and dorsal thinning that increased with se-
verity in a dose-dependent manner (fig. 4). To quantify
the penetrance and variability of these phenotypes, we
categorized embryos on the basis of the severity and ex-
tent of phenotypes: either poorly defined and irregularly
shaped somites and slightly widened notochord in mild-
to-moderately affected embryos (class I) or severe mis-
shaping and lack of definition of somites, misshapen no-
tochord, and significantly shorter body axes in severely
affected embryos (class II). Because these phenotypes were
consistent with those observed in morphants of other bbs
genes, including those expressing the atypical chaperonin
bbs6 and bbs10,18,20,26 we explored the possibility that there
may be genetic interaction or functional redundancy be-
tween these genes. Elsewhere, we reported that coinjec-
tion of bbs6 and bbs10 MOs resulted in a modest but clear
increase in the proportion of affected embryos.18 We found
that coinjection of bbs6 and bbs12 or bbs10 and bbs12
MOs resulted in a substantial increase in the proportion
of affected embryos (fig. 4). To explore the possibility that
these genes may exhibit redundancy in function, we
tested for suppression of all bbs chaperonin proteins.
Coinjection of bbs6, bbs10, and bbs12 at subeffective con-
centrations, which by themselves led to phenotypes in
!20% of embryos ( ), resulted in the most severen 1 100
increase in the proportion of affected embryos (fig. 4). For
instance, coinjection of MOs against bbs6 and bbs12 re-
sulted in 75% of embryos with CE-like phenotypes,
whereas a bbs10 and bbs12 combination injection yielded
∼80% affected embryos. Strikingly, simultaneous suppres-
sion of all three members of this chaperonin subgroup
gave rise to the most-severe phenotypes, both in terms of
penetrance, with 190% of embryos exhibiting CE defects
accompanied by other phenotypes that include cell de-
tachment along the embryonic axis and poor head defi-
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nition, and in terms of expressivity, with the severe (class
II) fraction of affected embryos expanding from !20% in
any single- or double-suppression combination to some
60% (fig. 4). These findings suggest that the three bbs
chaperonins may share redundant functions necessary for
proper embryo development.
Discussion
Identification of BBS genes has been based largely on ei-
ther traditional positional cloning approaches7–11 or, more
recently, comparative genomic approaches subtracting
likely ciliary genes from large regions of linkage that
would otherwise be experimentally intractable.12,16,17How-
ever, both approaches have significant limitations. Posi-
tional cloning requires large families for initial linkage,
which, for BBS, are scarce. The alternative, evolutionarily
based approaches, also fail to provide complete coverage,
as evident by the fact that BBS6, BBS10, and now BBS12
are only present in the vertebrate lineage.
Despite our very large sample of families with BBS (com-
bining cohorts from France and the United States), there
are no more large families available to us that would allow
singly the mapping of new BBS loci. We are thus using a
strategy of homozygosity mapping in smaller consan-
guineous families, looking for homozygous regions shared
by affected members of several families (each family show-
ing several potentially linked regions). The SNP Affymetrix
arrays allow much more efficient detection of homozy-
gous-by-descent regions than do standard whole-genome
microsatellite linkage scans (the 10K SNP array represents
an approximately eightfold gain in informativeness). A
similar approach has been reported recently by Nishimura
et al., leading to the identification of BBS9, as well as 19
additional possible candidate chromosomal regions that
do not map to any known BBS genes.17 Our analysis of
nine consanguineous families indeed pointed to a region
of potential linkage around 4q27 in three families (one of
which has no mutation detected to date). The most in-
formative one elicits a maximum LOD score of 2.05 (i.e.,
it is insufficient to prove linkage).
The identification of BBS12 provides further impetus in
the effort to describe the complete genetic load in BBS,
which is of significant clinical benefit. It is notable that
we detected pathogenic mutations in a variety of ethnic
groups, including Rom Gypsies, Europeans, Chinese, and
Middle Eastern and/or Arabic populations. One recurrent
mutation (F372fsX373) represents 20% of mutated alleles.
Since, in the analysis of the French cohort, families with
two bona fide mutations in another BBS gene were ex-
cluded from mutation screening, one can estimate that
the contribution of BBS12 to the total mutation load in
patients with BBS is ∼5%. This represents a significant im-
provement from the point of view of diagnostic and ge-
netics counseling, especially because there is a single cod-
ing exon to screen for mutations, compared with the
many exons present in most other BBS genes (with the
exception of BBS6, BBS10, and the very rarely mutated
BBS11).
With regard to oligogenic inheritance, only the US co-
hort (139 families) fully addressed this point, although
the French cohort also included all families in which a
single deleterious or probably deleterious allele had been
observed elsewhere.18,30 The absence of families with un-
ambiguously pathogenic mutations in two genes (table 2)
suggests that BBS12 is rarely involved in oligogenic in-
heritance. However, it is possible that some of the mis-
sense polymorphisms that are rather frequent in BBS12
may affect the severity of the phenotype, as observed for
a variant in the MGC1203 modifier gene, which affects
the efficiency of splicing by modulating the relative
strength of an exonic splice enhancer.26
The identification of BBS12 further highlights the im-
portant role of atypical type II chaperonins to the path-
ogenesis of this disorder, since the three BBS-causing chap-
eronin-like assemblies account for some 30% of the
mutation load in BBS, and to the function of cilia and
flagella in general. Our in silico analysis did not reveal
other similar chaperonins encoded in the human genome
that could indicate candidates for novel BBS genes. Both
BBS6 and BBS10 localize to the pericentriolar region of
basal bodies and centrosomes24 (N.K., unpublished data).
We predict that BBS12 is also likely to localize to the same
subcellular domain. It is notable that each of these mol-
ecules (BBS6, BBS10, and BBS12) arose in the vertebrate
lineage (or perhaps in chordates for BBS6), despite the fact
that both pericentriolar material components and the ar-
chitecture and broad function of the basal body and its
attached cilium have been conserved rigorously during
evolution. Some recent data have hinted at the possibility
that vertebrates have expanded the uses of cilia to trans-
duce a wide variety of morphogenetic signals.31 We spec-
ulate that the acquisition of new ciliary functions might
be coincident with the emergence of this branch of the
type II subfamily. Consistent with this notion, at least one
of these molecules, BBS6, was shown recently to be in-
volved in the planar cell polarity pathway, a noncanonical
Wnt pathway involved in the elaboration of structures in
three-dimensional space.20 As such, it will be important
to determine whether BBS6, BBS10, and BBS12 each play
overlapping roles in Wnt signal transduction. It is striking,
however, that despite the clear distinction in evolutionary
patterns of these three BBS genes compared with the eight
other known ones, there is no obvious clear-cut pheno-
typic difference linked to the nature of the mutated gene.
The identification of BBS12 allowed us to reanalyze the
evolution of the type II chaperonin superfamily. Typical
group II chaperonins are multisubunit assemblies of eight
proteins (a to z) known to be mainly involved in protein
folding. The three BBS genes are characterized by the con-
servation of the structural architecture called the “chap-
eronin fold,” but, in all three cases, with insertions of
extraneous sequences that do not share sequence similar-
ity with other chaperonins. Such insertions are not pre-
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sent in the nine other chaperonin subfamilies. They have
orthologues only in vertebrates, and they present a rapid
and parallel rate of evolution (fig. 3B). This distinguishes
them from the eight CCT chaperonins that appeared very
early in the evolution of eukaryotic organisms.29 Whereas
prototypic type II chaperonins have an ATPase hydrolysis
site that is important for their function, BBS12, like BBS6,24
appears to lack the key residues necessary for this activity.
This feature and the presence of insertions that would
prevent association with the canonical multimeric CCT
complex24 suggest a different mode of function.
The striking similarity in rapid evolution rate of BBS6,
BBS10, and BBS12 suggests that they have coevolved. Two
alternative hypotheses might be proposed: either the three
proteins interact in a common multisubunit complex or
they coevolved with other vertebrate-specific protein tar-
gets, involved in basal body and cilia assembly. Such pu-
tative vertebrate-specific proteins might then be targets
of BBS mutations. It is notable that suppression of each
of these chaperonin-like molecules in zebrafish yielded
highly overlapping phenotypes but, most intriguingly,
that simultaneous suppression of the entire subfamily
grossly exaggerated the penetrance and expressivity of
these phenotypes. We speculate that this might underlie
either some partial functional redundancy within the sub-
family or might reflect the progressive loss of pericentrio-
lar function, although the striking exacerbation of the ze-
brafish phenotype of triple morphants compared with any
double morphant combination suggests the former is the
more likely possibility.
In conclusion, the identification of BBS12, mutated in
5% of families with BBS, allowed the individualization of
a novel branch of vertebrate-specific chaperonin-related
proteins that account for one-third of the mutational load
in patients with BBS. It will be of major importance for
the understanding of the pathophysiology of this pleio-
tropic disease to analyze the cellular localization and func-
tion of the three chaperonin-related BBS proteins and the
nature of their interactions.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Bardet Biedl Syndrome: Multiple Alignment, http://bips.u-strasbg
.fr/BBS/ (for alignment of BBS12)
Ciliary Proteome Database, http://www.ciliaproteome.org/
CryptoDB, http://cryptodb.org/cryptodb/ (for cryptosporidia)
Cyanidioschyzon merolae Genome Project, http://merolae.biol.s
.u-tokyo.ac.jp/ (for C. merolae)
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/
dictyBase, http://dictybase.org/ (for D. discoideum)
Ensembl Genome Browser, http://www.ensembl.org/index.html
JGI: T. pseudonana, http://genome.jgi-psf.org/thaps1/thaps1
.home.html
NCBI, http://www.ncbi.nlm.nih.gov (for BBS12 [accession num-
bers NM_152618 and NP_689831])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for BBS)
PipeAlign, http://bips.u-strasbg.fr/PipeAlign/
Rice Information System, http://rise.genomics.org.cn/rice/index2
.jsp (for O. sativa)
The Institute for Genomic Research, http://www.tigr.org/ (for T.
thermophila)
The Wellcome Trust Sanger Institute, http://www.sanger.ac.uk/
(for E. histolytica and L. major)
TreeView, http://taxonomy.zoology.gla.ac.uk/rod/treeview.html
UCSC Genome Browser, http://genome.ucsc.edu/
UniProt, http://www.expasy.uniprot.org/ (for BBS12 [acces-
sion numbers Q6ZW61_HUMAN, Q7Z482_HUMAN, and
Q7Z342_HUMAN])
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